Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 3
1997 1
1998 1
1999 2
2004 1
2008 1
2009 1
2010 2
2011 5
2012 5
2013 10
2014 6
2015 29
2016 31
2017 26
2018 20
2019 35
2020 25
2021 27
2022 24
2023 35
2024 35
2025 40
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

326 results

Results by year

Filters applied: . Clear all
Page 1
CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy.
Liu ZD, Shi YH, Xu QC, Zhao GY, Zhu YQ, Li FX, Ma MJ, Ye JY, Huang XT, Wang XY, Xu X, Wang JQ, Zhao W, Yin XY. Liu ZD, et al. Cancer Lett. 2024 Mar 31;585:216640. doi: 10.1016/j.canlet.2024.216640. Epub 2024 Jan 28. Cancer Lett. 2024. PMID: 38290659 Free article.
Additionally, targeted silencing of CSNK2A1 expression significantly enhances sensitivity of PDAC cells to gemcitabine treatment. Mechanistically, CSNK2A1's transcriptional regulation is mediated by H3K27 acetylation in PDAC. Moreover, we identify CSNK2A1 as …
Additionally, targeted silencing of CSNK2A1 expression significantly enhances sensitivity of PDAC cells to gemcitabine treatment. Mec …
CSNK2A1 Promotes Gastric Cancer Invasion Through the PI3K-Akt-mTOR Signaling Pathway.
Jiang C, Ma Z, Zhang G, Yang X, Du Q, Wang W. Jiang C, et al. Cancer Manag Res. 2019 Dec 2;11:10135-10143. doi: 10.2147/CMAR.S222620. eCollection 2019. Cancer Manag Res. 2019. PMID: 31819646 Free PMC article.
However, the function and mechanism of CSNK2A1 in gastric cancer remain unclear, and this study aimed to elucidate the role of CSNK2A1 in gastric cancer. ...Stable cancer cell lines with CSNK2A1 gene overexpression or knockdown were established to investigate …
However, the function and mechanism of CSNK2A1 in gastric cancer remain unclear, and this study aimed to elucidate the role of CSN …
CK2alpha/CSNK2A1 Induces Resistance to Doxorubicin through SIRT6-Mediated Activation of the DNA Damage Repair Pathway.
Hussein UK, Ahmed AG, Song Y, Kim KM, Moon YJ, Ahn AR, Park HS, Ahn SJ, Park SH, Kim JR, Jang KY. Hussein UK, et al. Cells. 2021 Jul 13;10(7):1770. doi: 10.3390/cells10071770. Cells. 2021. PMID: 34359939 Free PMC article.
CK2alpha/CSNK2A1 is involved in cancer progression by phosphorylating various signaling molecules. ...U2OS and KHOS/NP osteosarcoma cells with induced overexpression of CSNK2A1 were resistant to the cytotoxic effects of doxorubicin, and the knock-down of CSNK2A1 …
CK2alpha/CSNK2A1 is involved in cancer progression by phosphorylating various signaling molecules. ...U2OS and KHOS/NP osteosarcoma c …
P300 increases CSNK2A1 expression which accelerates colorectal cancer progression through activation of the PI3K-AKT-mTOR axis.
Liu J. Liu J. Exp Cell Res. 2023 Sep 1;430(1):113694. doi: 10.1016/j.yexcr.2023.113694. Epub 2023 Jun 28. Exp Cell Res. 2023. PMID: 37391010
Results revealed that both the mRNA and protein levels of CSNK2A1 in HCT116, SW480, HT29, SW620 and Lovo cells were upregulated. Additionally, P300-mediated H3K27ac activation at the CSNK2A1 promoter was found to drive the increase in CSNK2A1 expression. Tran …
Results revealed that both the mRNA and protein levels of CSNK2A1 in HCT116, SW480, HT29, SW620 and Lovo cells were upregulated. Addi …
CSNK2A1-mediated MAX phosphorylation upregulates HMGB1 and IL-6 expression in cholangiocarcinoma progression.
Yang B, Zhang J, Wang J, Fan W, Barbier-Torres L, Yang X, Justo MAR, Liu T, Chen Y, Steggerda J, Ramani K, Lu SC, Yang H. Yang B, et al. Hepatol Commun. 2023 Jun 22;7(7):e00144. doi: 10.1097/HC9.0000000000000144. eCollection 2023 Jul 1. Hepatol Commun. 2023. PMID: 37347224 Free PMC article.
RESULTS: Expression of MAX, CSNK2A1, C-MYC, beta-catenin, HMGB1, and IL-6 was upregulated in hepatic cells from CCA liver tissue. ...MAX positively regulated IL-6 and HMGB1 through paracrine signaling in HepG2, LX2, and RAW cells and autocrine signaling in MzChA-1 cells. …
RESULTS: Expression of MAX, CSNK2A1, C-MYC, beta-catenin, HMGB1, and IL-6 was upregulated in hepatic cells from CCA liver tissue. ... …
CSNK2A1-mediated phosphorylation of HMGA2 modulates cisplatin resistance in cervical cancer.
Shi Z, Wu D, Xu H, Yang J, Sun X. Shi Z, et al. FEBS Open Bio. 2021 Aug;11(8):2245-2255. doi: 10.1002/2211-5463.13228. Epub 2021 Jul 12. FEBS Open Bio. 2021. PMID: 34115920 Free PMC article.
We performed liquid chromatography-tandem mass spectrometry to demonstrate that HMGA2 has high potential to interact with casein kinase II A1 (CSNK2A1). Moreover, we observed that HMGA2 co-localizes with CSNK2A1 in the nucleus by immunofluorescence. Binding of HMGA2 …
We performed liquid chromatography-tandem mass spectrometry to demonstrate that HMGA2 has high potential to interact with casein kinase II A …
Inherited CSNK2A1 variants in families with Okur-Chung neurodevelopmental syndrome.
Belnap N, Price-Smith A, Ramsey K, Leka K, Abraham A, Lieberman E, Hassett K, Potu S, Rudy N, Smith K, Mikhail FM, Monaghan KG, Hendershot A, Mourmans J, Descartes M, Huentelman MJ, Sills J, Rangasamy S, Narayanan V. Belnap N, et al. Clin Genet. 2023 Nov;104(5):607-609. doi: 10.1111/cge.14408. Epub 2023 Jul 25. Clin Genet. 2023. PMID: 37491870
DUSP2 recruits CSNK2A1 to suppress AKT1-mediated apoptosis resistance under hypoxic microenvironment in pancreatic cancer.
Zhang Y, Kong R, Yang W, Hu K, Zhao Z, Li L, Geng X, Liu L, Chen H, Xiao P, Liu D, Luo Y, Chen H, Hu J, Sun B. Zhang Y, et al. Cancer Lett. 2023 Aug 1;568:216288. doi: 10.1016/j.canlet.2023.216288. Epub 2023 Jun 29. Cancer Lett. 2023. PMID: 37390887
Mechanistically, DUSP2 competed with AKT1 to bind to casein kinase 2 alpha 1 (CSNK2A1) and inhibited the phosphorylation of AKT1, which plays a crucial role in apoptosis resistance. Interestingly, aberrant activation of AKT1 resulted in an increase in the ubiquitin E3 liga …
Mechanistically, DUSP2 competed with AKT1 to bind to casein kinase 2 alpha 1 (CSNK2A1) and inhibited the phosphorylation of AKT1, whi …
326 results